Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tezepelumab

tezepelumab

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tezepelumab

10 trials tracked of tezepelumab: 4 in phase 3 or 4 and 4 with published results. The most-cited published study has 149 citations.

10Trials tracked
4Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 4 Phase 2 2 Phase 1 4
  1. Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma Completed · 149 cited
  2. Phase 3 Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma Completed · 149 cited
  3. Phase 3 Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma Completed · 19 cited
  4. Phase 3 Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma Completed · 6 cited
  5. Phase 2 Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) Completed
  6. Phase 2 Tezepelumab COPD Exacerbation Study Completed
Show 4 more trials
  1. Phase 1 Safety Study of Tezepelumab (AMG 157) in Healthy Adults Completed
  2. Phase 1 Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis Completed
  3. Phase 1 Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma Completed
  4. Phase 1 Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Biologics provide effective and long-lasting disease control for chronic rhinosinusitis with nasal polyps
Allergy & Immunology Sys. Review
Biologics provide effective and long-lasting disease control for chronic rhinosinusitis with nasal polyps Biologics May Help Chronic Sinusitis With Nasal Polyps
This narrative review examines the efficacy of biologics, including dupilumab, mepolizumab, omalizumab, and tezepelumab, for patients with c…
A new review suggests biologic drugs may improve sinus symptoms, smell, and asthma in people with nasal polyps.
Frontiers Sep 11, 2026
Tezepelumab significantly improved smell and taste scores in adults with chronic rhinosinusitis with nasal polyps over fifty-two weeks of treatment
Drug Pipeline RCT
Tezepelumab significantly improved smell and taste scores in adults with chronic rhinosinusitis with nasal polyps over fifty-two weeks of treatment New drug restores smell for chronic sinusitis patients quickly
In a Phase 3 trial, tezepelumab demonstrated superior efficacy over placebo for improving smell and taste in adults with uncontrolled chroni…
A new drug helps people with chronic sinusitis regain their sense of smell much faster than standard treatments allow
May 6, 2026
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies
Allergy & Immunology Meta-analysis
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies Switching Asthma Drugs Could Change Your Life
A systematic review and meta-analysis of 2,292 patients found that switching biologics significantly reduced exacerbations and improved asth…
If your severe asthma medication stops working, switching to a different biologic drug could cut your attacks in half and help you breathe e…
May 5, 2026
Narrative review discusses tezepelumab for severe asthma in type 2-low patients on GINA Step 4–5 therapy
Drug Pipeline Sys. Review
Narrative review discusses tezepelumab for severe asthma in type 2-low patients on GINA Step 4–5 therapy New Asthma Drug Works for Hard-to-Treat Patients Who Had Few Options
This narrative review examines tezepelumab for severe asthma, specifically focusing on type 2-low patients currently prescribed GINA Step 4–…
This new treatment offers hope for severe asthma patients who don’t respond to standard therapies, including a group previously left out of …
Frontiers Apr 24, 2026